Cancer Immunotherapy Market Value By Technology Type (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others), and By End user (Hospitals, Cancer Research Centers, and Clinics), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Industry Analysis, Share & Forecast, 2023 - 2032

  • ID: 354 |  
  • Published date: April, 2023  |  
  • Report Format: PDF

Recent update: Our research team is keeping a close eye on the potential impact of COVID-19 and other global crises on various industries worldwide, allowing us to stay ahead of the competition.

Market Overview:

Cancer Immunotherapy Market size was valued at USD 85.1 Billion in 2022 and is expected to showcase a CAGR of over 7.5% from 2023 to 2032. By the end of the forecast period, the market is anticipated to surpass USD 298.2 Billion.

To get more info about this report - 

The global cancer immunotherapy market refers to the use of the immune system to treat cancer. It involves the use of various therapies that stimulate or enhance the body's immune response to identify and attack cancer cells. Cancer vaccines, monoclonal antibodies, cell therapies, and immune checkpoint inhibitors are the most common types of cancer immunotherapy. 

Cancer Immunotherapy Market Value Insights

Report Coverage


Base Year


Market Size in 2022

USD 85.1 Billion

Forecast Period

2023 to 2032

CAGR (2023 to 2032)


Forecast Year Value, 2032

USD 298.2 Billion

Historical Data for

2019 to 2022

Segment Covered

Technology Type, Application, End user, Region

Companies Covered

  • Novartis AG
  • Bristol-Myers Squibb Company
  • Genentech, Inc 
  • Pfizer Inc.
  • AstraZeneca
  • Lilly
  • and more.


To get more info about this report - 


Monoclonal antibodies are artificially created antibodies that can target specific cancer cells, while immune checkpoint inhibitors are designed to prevent cancer cells from evading the immune system. Cancer vaccines stimulate the immune system to recognize and destroy cancer cells, and cell therapies involve the use of genetically modified immune cells to target cancer cells. Cancer immunotherapy is a type of cancer treatment that improves the immune system's ability to combat cancer. Immunotherapy works by directing the immune system's attention to cancer-specific targets, activating the immune system to mobilize the target, and inducing a response capable of destroying cancer cells. 

Growth Factors: 

Increasing prevalence of cancer: The growing incidence of cancer worldwide is a major driver of the cancer immunotherapy market. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with an estimated 9.6 million deaths in 2018. The rise in cancer cases is creating a high demand for effective cancer treatments, including immunotherapy. 

Increasing investments in research and development: Pharmaceutical and biotechnology companies are investing heavily in research and development to develop new and effective cancer immunotherapies. This investment is helping to expand the market and drive growth by introducing new treatments and expanding the applications of immunotherapy. 

Restraining Factors:

High cost of immunotherapy: Cancer immunotherapy is often expensive, making it unaffordable for many patients. This is a major challenge, especially in developing countries where access to affordable cancer treatment is limited. 

Adverse effects: Like any medical treatment, immunotherapy can have adverse effects, ranging from mild to severe. These adverse effects can limit the use of immunotherapy in some patients and may also affect patient adherence to the treatment regimen.

By Technology Type Synopsys:  

Based on the technology type, the cancer immunotherapy market is classified into monoclonal antibodies, cytokines & immunomodulators, and others. Among these, the monoclonal antibodies segment is anticipated to hold the largest share of global cancer immunotherapy industry over the predicted timeframe, owing to their wide range of applications in cancer treatment and their proven efficacy. 

There are currently several monoclonal antibodies approved for use in cancer treatment, including trastuzumab for breast cancer, rituximab for lymphoma, and pembrolizumab for several types of cancer including melanoma, lung cancer, and bladder cancer. The development of monoclonal antibodies involves creating large numbers of identical antibodies that can bind to a specific protein on the surface of cancer cells. 

These antibodies can then trigger an immune response, leading to the destruction of the cancer cells. Ongoing research and development in this field will likely lead to the development of new and innovative therapies that will further improve cancer outcomes for patients.

Regional Overview:

North America holds the largest market share in the global cancer immunotherapy market, primarily due to the high prevalence of cancer in the region and the availability of advanced healthcare infrastructure. The region also has a large number of pharmaceutical and biotechnology companies that are actively engaged in research and development of cancer immunotherapies.

The Asia-Pacific region is anticipated to witness the fastest growth in the global cancer immunotherapy market due to the increasing prevalence of cancer, growing healthcare infrastructure, and rising healthcare spending in countries such as China and India. The region is also home to a large number of pharmaceutical companies that are investing in the development of cancer immunotherapies.

Europe is also a significant market for cancer immunotherapy, with countries such as Germany and the UK being major contributors to the growth of the market in the region. The growing aging population and increasing incidence of cancer are driving the demand for cancer immunotherapies in the region.

Key Development:

  • On September 2021, Bristol-Myers Squibb Company polled 250 oncologists, surgeons, and specialists from the US, Germany, and Japan. The survey revealed that immunotherapy holds great promise for cancers detected at an early stage.
  • On May 2021, The European Commission has approved Astellas Pharma's XTANDI therapy (enzalutamide). XTANDI is the only oral development and evaluation for non-metastatic, metastatic hormone sensitive, and metastatic castration resistant prostate cancer.

Top companies include in the global cancer immunotherapy market are:

  • Novartis AG
  • Bristol-Myers Squibb Company
  • Genentech, Inc  
  • Pfizer Inc.
  • AstraZeneca
  • Lilly
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Immunocore, Ltd
  • Others

To get more info about this report - 

In-depth analysis of cancer immunotherapy market along with industry coverage and forecasting for the following segments:

Market Value, By Technology Type

  • Monoclonal Antibodies 
  • Cytokines & Immunomodulators
  • Others

Market Value, By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer 
  • Head & Neck Cancer
  • Others

Market Value, By End User

  • Hospitals
  • Cancer Research Centers
  • Clinics

Market Value, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Frequently Asked Questions (FAQ):

Publisher: Market Value Insights


  • $3500

  • $4500
  • $5500

Get in Tuch With Us